The effects of lifarizine in acute cerebral infarction: A pilot safety study

Cerebrovascular Diseases

Volumn 6, Issue 3, 1996, Pages 156-160

  Squire, I B ^a   Lees, K R ^a   Pryse Phillips, W ^b   Kertesz, A ^c   Bamford, J ^d  

^a WESTERN INFIRMARY   (United Kingdom)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^c Department of Clinical Neurological Sciences ^*  (Canada)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Cerebral infarction; Lifarizine

Indexed keywords

LIFARIZINE;

ADULT; AGED; ARTICLE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE;

EID: 0029873354     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000108016     Document Type: Article

References (12)

1. Lees KR: Therapeutic interventions in acute stroke. Br J Clin Pharmacol 1992;34:486-493.
2. Hommel M, Boissel JP, Cornu C, Boutitie F, Lees KR, Besson G, Leys D, Amarenco P, Bogaert M: Termination of trial of streptokinase in severe acute ischaemic stroke. Lancet 1995:345:57.
3. Sheridan RD, Patmore L, Spedding M: The novel neuroprotective agent RS-87476 potently inhibits sodium currents in mouse neuroblastoma. Br J Pharmacol 1991; 104(suppl): P 25.
4. Fraser S, Spedding M: RS-87476. a novel neu-roprotective agent, antagonises the effects of calcium channel activators in guinea-pig taenia. BrJ Pharmacol 1991; 104(suppl):p 156.
5. Kucharczyk J, Mintorovilch J, Moseley ME, Asgari HS, Sevick RJ, Derugin N, Norman D: Ischaemic brain damage: Reduction by sodium-calcium ion channel modulator RS 87476. Radiology 1991;179:221-227.
6. Rankin J: Cerebrovascular accidents in patients over the age of 60. II. Prognosis. Scott Med J 1957;2:200-215.
7. Mahoney FI, Barthel DW: Functional evaluation: The Barthel Index. Md State Med J 1965; 14:61-65.
8. Goldstein LB, Bertels C, Davis JN: Inter-rater reliability of the NIH stroke scale. Arch Neurol 1989:45:660-662.
9. Cote R, Battista RN, Woolfson C, Boucher J, Adam J, Hachinski V: The Canadian Neurological Scale: Validation and reliability assessment. Neurology 1989;39:638-643.
10. Pearson HA, Warning CJ, Young MA, Beard M: A study to investigate the safety and pharmacokinetics of three five-day multiple dose regimes of RS-87476 in healthy male volunteers aged 70-80 years. Syntex study No. 15385/013, SRS report No. SS/U7/90, CL5590.1990.
11. Wahlgren NG, MacMahon DG, De Kevser J, Indredavik B, Ryman T: Intravenous Nimodipine West European Stroke Trial (IN WEST) of nimodipinc in the treatment of acute ischaemic stroke. Cerebrovasc Dis 1994;4:204-210.
12. Muir KW, Grosset DG, Gamzu E, Lees KR: Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers. BrJ Clin Pharmacol 1994;38:33-38.